GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ENDRA Life Sciences Inc (NAS:NDRA) » Definitions » PB Ratio

ENDRA Life Sciences (ENDRA Life Sciences) PB Ratio : 0.59 (As of May. 03, 2024)


View and export this data going back to 2017. Start your Free Trial

What is ENDRA Life Sciences PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-03), ENDRA Life Sciences's share price is $0.322. ENDRA Life Sciences's Book Value per Share for the quarter that ended in Dec. 2023 was $0.55. Hence, ENDRA Life Sciences's PB Ratio of today is 0.59.

The historical rank and industry rank for ENDRA Life Sciences's PB Ratio or its related term are showing as below:

NDRA' s PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 1.17   Max: 6.69
Current: 0.59

During the past 10 years, ENDRA Life Sciences's highest PB Ratio was 6.69. The lowest was 0.01. And the median was 1.17.

NDRA's PB Ratio is ranked better than
89% of 209 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.12 vs NDRA: 0.59

During the past 12 months, ENDRA Life Sciences's average Book Value Per Share Growth Rate was -76.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -49.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -46.40% per year.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of ENDRA Life Sciences was 30.50% per year. The lowest was -49.40% per year. And the median was -37.60% per year.

Back to Basics: PB Ratio


ENDRA Life Sciences PB Ratio Historical Data

The historical data trend for ENDRA Life Sciences's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ENDRA Life Sciences PB Ratio Chart

ENDRA Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.97 3.56 2.83 1.79 3.89

ENDRA Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.79 1.61 1.51 1.80 3.89

Competitive Comparison of ENDRA Life Sciences's PB Ratio

For the Diagnostics & Research subindustry, ENDRA Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ENDRA Life Sciences's PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where ENDRA Life Sciences's PB Ratio falls into.



ENDRA Life Sciences PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

ENDRA Life Sciences's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=0.322/0.545
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


ENDRA Life Sciences  (NAS:NDRA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


ENDRA Life Sciences PB Ratio Related Terms

Thank you for viewing the detailed overview of ENDRA Life Sciences's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ENDRA Life Sciences (ENDRA Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
3600 Green Court, Suite 350, Ann Arbor, MI, USA, 48105-1570
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Executives
Michael Milos Thornton officer: Chief Technology Officer 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Anthony Digiandomenico director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Alexander Y Tokman director C/O MICROVISION, INC., 6222 185TH AVENUE NE, REDMOND WA 98052
Francois Roger Michelon director, officer: Chief Executive Officer 430 N. JUNO LANE, JUNO BEACH FL 33406
Lou Basenese director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Irina Pestrikova officer: Senior Director, Finance 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Renaud Bertrand Maloberti officer: Chief Commercial Officer 10 ACORN WAY, GEORGETOWN MA 01833
David R. Wells officer: Chief Financial Officer 2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Michael Harsh director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Longboard Capital Advisors, Llc 10 percent owner 9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad 10 percent owner 1312 CEDAR ST., SANTA MONICA CA 90405
Sanjiv Sam Gambhir director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105